~~<i id='F46500CD03'><strike id='F46500CD03'><tt id='F46500CD03'><pre id='F46500CD03'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：focus 2025-10-01 18:22:29 Page View：826

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： WHO calls for emergency meeting on new China virus, as cases spread
Next article： Activists slam private health insurers over coverage restrictions

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

AdobeThehealthrecordscompanyNextGenHealthcarewillpay$31milliontoresolveallegationsthatitpaidkickback

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

2:04ACanadairfirefightingplanesprayswaterduringafireinDervenochoria,north-westofAthens,onJuly19,2023